These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33982133)

  • 21. What Do We Know About Remdesivir Drug Interactions?
    Yang K
    Clin Transl Sci; 2020 Sep; 13(5):842-844. PubMed ID: 32402130
    [No Abstract]   [Full Text] [Related]  

  • 22. Update Alert 2: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).
    Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Miller MC; Forciea MA; Humphrey LL;
    Ann Intern Med; 2021 Dec; 174(12):W116-W117. PubMed ID: 34606308
    [No Abstract]   [Full Text] [Related]  

  • 23. Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study.
    Flisiak R; Zarębska-Michaluk D; Berkan-Kawińska A; Tudrujek-Zdunek M; Rogalska M; Piekarska A; Kozielewicz D; Kłos K; Rorat M; Bolewska B; Szymanek-Pasternak A; Mazur W; Lorenc B; Podlasin R; Sikorska K; Oczko-Grzesik B; Iwaszkiewicz C; Szetela B; Pabjan P; Pawłowska M; Tomasiewicz K; Polańska J; Jaroszewicz J
    Pol Arch Intern Med; 2021 Jan; 131(1):103-110. PubMed ID: 33382547
    [No Abstract]   [Full Text] [Related]  

  • 24. 'A very, very bad look' for remdesivir.
    Cohen J; Kupferschmidt K
    Science; 2020 Nov; 370(6517):642-643. PubMed ID: 33154114
    [No Abstract]   [Full Text] [Related]  

  • 25. Remdesivir (Veklury) for COVID-19.
    Med Lett Drugs Ther; 2020 Nov; 62(1612):186-188. PubMed ID: 33443491
    [No Abstract]   [Full Text] [Related]  

  • 26. Major Update 2: Remdesivir for Adults With COVID-19.
    Finsterer J
    Ann Intern Med; 2022 Aug; 175(8):W81. PubMed ID: 35969872
    [No Abstract]   [Full Text] [Related]  

  • 27. Major Update 2: Remdesivir for Adults With COVID-19.
    Kaka AS; Wilt TJ
    Ann Intern Med; 2022 Aug; 175(8):W81-W82. PubMed ID: 35969873
    [No Abstract]   [Full Text] [Related]  

  • 28. Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19.
    Kaur A; Chaudhary G; Singh P; Arora S; Kaur R
    Curr Drug Targets; 2021; 22(13):1536-1547. PubMed ID: 33371833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
    Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating the effectiveness of remdesivir on risk of COVID-19 mortality: The role of observational data.
    Giacomelli A; Cozzi-Lepri A; Casalini G; Oreni L; Ridolfo AL; Antinori S
    Pharmacol Res; 2022 Jul; 181():106268. PubMed ID: 35605811
    [No Abstract]   [Full Text] [Related]  

  • 31. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients.
    Weinbergerova B; Mayer J; Kabut T; Hrabovsky S; Prochazkova J; Kral Z; Herout V; Pacasova R; Zdrazilova-Dubska L; Husa P; Bednar P; Ruzek D; Lengerova M
    Hematol Oncol; 2021 Dec; 39(5):715-720. PubMed ID: 34396566
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA Approval of Remdesivir - A Step in the Right Direction.
    Rubin D; Chan-Tack K; Farley J; Sherwat A
    N Engl J Med; 2020 Dec; 383(27):2598-2600. PubMed ID: 33264539
    [No Abstract]   [Full Text] [Related]  

  • 33. Remdesivir: A giant step, or a tiptoe?
    Dickinson GM
    Clin Dermatol; 2020; 38(6):773-774. PubMed ID: 32405143
    [No Abstract]   [Full Text] [Related]  

  • 34. Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19.
    Chua KP; Conti RM
    JAMA Intern Med; 2020 Oct; 180(10):1273-1274. PubMed ID: 32804187
    [No Abstract]   [Full Text] [Related]  

  • 35. Use of Remdesivir in Myasthenia gravis and COVID-19.
    Peters BJ; Rabinstein AA; DuBrock HM
    Pharmacotherapy; 2021 Jun; 41(6):546-550. PubMed ID: 33835512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
    Ko WC; Rolain JM; Lee NY; Chen PL; Huang CT; Lee PI; Hsueh PR
    Int J Antimicrob Agents; 2020 Apr; 55(4):105933. PubMed ID: 32147516
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacokinetics of GS-441524, the active metabolite of remdesivir, in patients receiving continuous renal replacement therapy: A case series.
    Nishikawa A; Ito I; Yonezawa A; Itohara K; Matsubara T; Sato Y; Matsumura K; Hamada S; Tanabe N; Kai S; Imoto E; Yoshikawa K; Ohtsuru S; Yanagita M; Hirai T; Terada T
    J Infect Chemother; 2024 Apr; 30(4):348-351. PubMed ID: 37866621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Not Available].
    Wu PE; Morris AM
    CMAJ; 2021 Apr; 193(14):E495-E496. PubMed ID: 33824151
    [No Abstract]   [Full Text] [Related]  

  • 39. Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process.
    Ison MG; Wolfe C; Boucher HW
    JAMA; 2020 Jun; 323(23):2365-2366. PubMed ID: 32407438
    [No Abstract]   [Full Text] [Related]  

  • 40. Concentrations of remdesivir and GS-441524 in human milk from lactating individuals diagnosed with COVID-19.
    Bertrand K; Sepulveda Y; Spiegel BJ; Best BM; Suhandynata R; Rossi S; Chambers CD; Momper JD
    Pediatr Res; 2024 Jul; 96(2):269-272. PubMed ID: 38347172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.